Drugs / REVAXIS®
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT01287949 | Jan 2011 → May 2012 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00447525 | Feb 2007 → Jan 2008 | diphtheria, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00400309 | Jun 2006 → Feb 2007 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT05193734 Comparator | Feb → Aug 2022 | pertussis | University Hospital, Geneva | Unknown | No outcome recorded |
| Phase 3 | NCT01277705 Comparator | Jan → Apr 2002 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Revaxis | “Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS)” NCT01287949 ↗ |
| Modality | Vaccine | “Tetanus, Diphtheria, Poliomyelitis vaccine (REVAXIS®)” NCT00400309 ↗ |
| Route | Intramuscular | “Children were randomly assigned to receive a single intramuscular dose of REVAXIS or DT Polio.” PMID 21441781 ↗ May 2011 |